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Legends to Supplementary Figures and Tables: 
 
Supplementary Figure 1. Technical validation of MMP-9 serum levels in DMD. A-B. Scatter 
plots showing significant correlations between serum and plasma MMP-9 levels in 111 serum 
and plasma samples obtained from DMD patients at the same moment using the ELISA assay 
(A) and in 60 serum and plasma samples as determined by antibody array (B). Serum levels are 
plotted on the x-axis, plasma levels on the y-axis. AU is arbitrary units. C-D. Scatter plots 
showing significant correlations between MMP-9 levels measured by ELISA and antibody 
array in 60 serum (C) and plasma samples (D). Each dot represents an independent patient 
sample. ELISA measurements are plotted on the x-axis, antibody array measurements on the y-
axis. Spearman correlation was used to test whether significant associations exist. E. MMP-9 
characterization by gelatin zymography. Example of gelatin zymography for 10 cases. Pro-
MMP-9 and pro-MMP-2 are present in all samples, while the active forms are not detected. The 
control standard (S) shows both pro-active forms and the active form of MMP-2. L is molecular 
ladder. F. Scatter plot showing the correlation (Spearman) between serum MMP-9 values 
measured by ELISA (x-axis) and Pro-MMP-9 band intensity in the gelatin zymography assay 
(y-axis). No significant correlation was found between pro-MMP-2 band intensities and MMP-
9 ELISA measurements. Each dot represents one of 29 DMD patients.  
 
Supplementary Figure 2. Scatter plot showing serum levels of MMP-9 during the dose 
escalation study and the open-label extension study of study NCT01910649. MMP-9 levels are 
plotted on the y-axis while visits are plotted on the x-axis. Visits 2 to 12 are part of the dose 
escalating study, between visit 12 and 13 patients were not treated and this period varies 
between 9 to 47 weeks. Visit 13 represents the start of the open label extension study. 
 Supplementary Figure 3. Scatterplot showing the lack of association between serum MMP-9 
and muscle leakage biomarkers. MMP-9 levels are plotted with CK (A) and LDH (B). A high 
correlation is present between CK and LDH levels for all patients involved in the phase 3 trial 
(NCT01254019, DMD114044) at baseline (C). 
 
Supplementary Figure 4. Scatterplot showing the association between MMP-9 and duration 
of corticosteroid treatment. A. Plot showing the association between patients age and duration 
of corticosteroid treatment. B. Scatterplot showing the relationship between serum MMP-9 and 
duration of treatment with corticosteroids divided by age groups. For both panels the color 
represent age bins of 1 year starting from 5 years of age up to 14. 
 
Supplementary Table 1. MMP-9 levels in healthy/ non DMD children reported in literature 
and in this manuscript. 
Supplementary Table 2. DMD patients belonging to the natural history cohorts involved in 
the longitudinal study.  
 
 
 
